Resonancia magnética cardíaca en la miocardiopatía hipertrófica: un paso más allá del diagnóstico
DOI:
https://doi.org/10.37615/retic.n1a4Palabras clave:
Miocardiopatía hipertrófica, Cardio-RM, Miocardiopatías, Fibrosis miocárdica, Gadolinio.Resumen
La miocardiopatía hipertrófica es la enfermedad genética más frecuente en el mundo. Se ha asociado con muerte súbita en uno de cada tres casos en jóvenes y deportistas. La diversidad fenotípica de esta patología se estudió por ecocardiografía durante años, pero es la resonancia magnética la que brinda otra visión. El estudio de las diferentes hipertrofi as, la fi brosis, el edema miocárdico, el disarray de fi bras y los cambios morfológicos que ocurren antes de la hipertrofi a ventricular son algunos de los aportes que brinda el método. La utilización de estos hallazgos hará en un futuro cercano más correcta la toma de decisiones para una prevención primaria.
Descargas
Métricas
Citas
Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92: 785-789. DOI: https://doi.org/10.1161/01.CIR.92.4.785
Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter-defi brillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405-412. DOI: https://doi.org/10.1001/jama.298.4.405
Olivotto I, Girolami F, Sciagra R, Ackerman MJ, Sotgia B, Bos JM, et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofi lament gene mutations. J Am Coll Cardiol 2011; 58: 839-848. DOI: https://doi.org/10.1016/j.jacc.2011.05.018
Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270-276. DOI: https://doi.org/10.1093/eurheartj/ehm342
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron PH, et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal 2014; 35: 2.733-2.779.
Eriksson MJ, Sonnenberg B, Woo A, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39: 638-645.
Germans T, Wilde AA, Dijkmans PA, ChaiW, Kamp O, Pinto YM, van Rossum AC. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol 2006; 48: 2.518-2.523. DOI: https://doi.org/10.1016/j.jacc.2006.08.036
Devlin AM, Moore NR, Ostman-Smith I. A comparison of MRI and echocardiography in hypertrophic cardiomyopathy. Br J Radiol 1999; 72 (855): 258- 264. DOI: https://doi.org/10.1259/bjr.72.855.10396215
Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy. Circulation 2005; 112: 855-861. DOI: https://doi.org/10.1161/CIRCULATIONAHA.104.507723
Olszewski R, Timperley J, Szmigielski C, Monaghan M,Nihoyannopoulos P, Senior R, et al. The clinical applications of contrast echocardiography. Eur J Echocardiogr 2007; 8: S13-23. DOI: https://doi.org/10.1016/j.euje.2007.03.021
Maron MS, Maron BJ, Harrigan C, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009; 54: 220-228. DOI: https://doi.org/10.1016/j.jacc.2009.05.006
To ACY, Dhillon A, Desai MY. Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy. J Am Coll Cardiol Img 2011; 4 (10): 1.123-1.137. DOI: https://doi.org/10.1016/j.jcmg.2011.06.022
Sakamoto T, Tei C, Murayama M. Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. Jpn Heart J 1976; 17: 611-629. DOI: https://doi.org/10.1536/ihj.17.611
Yamaguchi H, Ishimura T, Nishiyama S. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy). Ventriculographic and echocardiographic features in 30 patients. Am J Cardiol 1979; 44: 401-412. DOI: https://doi.org/10.1016/0002-9149(79)90388-6
Eriksson MJ, Sonnenberg B, Woo A, Rakowski P, Parker TG, Wigle ED, Rakowski H. Long-Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39 (4): 638-645. DOI: https://doi.org/10.1016/S0735-1097(01)01778-8
Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010; 3: 51-58. DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.109.854026
Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010; 56: 875- 887. DOI: https://doi.org/10.1016/j.jacc.2010.05.007
James C, Moon JC. ¿Qué signifi ca la captación tardía del Gadolinio en la miocardiopatía hipertrófi ca? Rev Esp Cardiol 2007; 60 (1): 1-4. DOI: https://doi.org/10.1016/S0300-8932(07)74976-X
GreenJJ, Berger JS, Kramer ChM, Salerno M. Prognostic Value of Late Gadolinium Enhancement in Clinical Outcomes for Hypertrophic Cardiomyopathy. J Am Coll Cardiol Img 2012; 5: 370-377. DOI: https://doi.org/10.1016/j.jcmg.2011.11.021
Moon JC, Reed E, Sheppard MN, Elkington AG, Ho S, Burke M, Petrou M, Pennell DJ. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 43: 2.260-2.264. DOI: https://doi.org/10.1016/j.jacc.2004.03.035
Chan RH, Maron BJ, Olivotto I, Pencina MJ, Maron MS. Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. Circulation 2014; 130: 484-495. DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.007094
Unverferth DV, Baker PB, Pearce LI, Lautman J, Roberts WC. Regional myocyte hypertrophy and increased interstitial myocardial fibrosis in hypertrophic cardiomyopathy. Am J Cardiol 1987; 59: 932-936. DOI: https://doi.org/10.1016/0002-9149(87)91128-3
Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz R, Schulz-Menger J. Noninvasive detection of fi brosis applying contrast-enhanced cardiac magnetic resonance in diff erent forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009; 53 (3): 284-291. DOI: https://doi.org/10.1016/j.jacc.2008.08.064
Nakanishi S, Nishiyama S, Nishimura S, Yamaguchi H, Matsuya S. Histological features of apical hypertrophic cardiomyopathy. J Cardiogr 1985; Suppl: 3-11.
Moon JC, Mogensen J, Elliott PM, et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 2005; 91: 1.036-1.040. DOI: https://doi.org/10.1136/hrt.2004.041384
Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, Moon JC. Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diff use Myocardial Fibrosis: Preliminary Validation in Humans. Circulation 2010; 122: 138-144. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.930636
Harrigan CJ, Appelbaum E, Maron BJ, et al. Signifi cance of papillary muscle abnormalities identifi ed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2008; 101: 668-673. DOI: https://doi.org/10.1016/j.amjcard.2007.10.032
Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992; 85: 1.651-1.660. DOI: https://doi.org/10.1161/01.CIR.85.5.1651
Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron BJ. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011; 124: 40-47. DOI: https://doi.org/10.1161/CIRCULATIONAHA.110.985812
Schantz D, Benson L, Windram J, Wong D, Dragulescu A, Yoo SJ, Mertens L, Friedberg M, Al Nafi si B, Grosse-Wortmann L. Abnormal Mitral Valve Dimensions in Pediatric Patients with Hypertrophic Cardiomyopathy. Pediatr Cardiol 2016. Epub ahead of print. DOI: https://doi.org/10.1007/s00246-016-1351-5
Patel P, Dhillon A, Popovic ZB, Smedira NG, Rizzo J, Hamilarasan M, Agler D, Lytle BW, Lever HM, Desai MY. Left Ventricular Outfl ow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy. Cardiovasc Imaging 2015; 8: e003132.
Crawford MH, Ananthasubramaniam K. Hypertrophic cardiomyopathy. In: Current Diagnosis & Treatment: Cardiology. 4.th edition. McGraw-Hill Education. New York, USA. 2014; 301-313.
Sivanandam A, Ananthasubramaniam K. Midventricular Hypertrophic Cardiomyopathy with Apical Aneurysm: Potential for Underdiagnosis and Value of Multimodality Imaging. Hindawi Publishing Corporation Case Reports in Cardiology. Volume 2016; Article ID 9717948. DOI: https://doi.org/10.1155/2016/9717948
Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA, Selvanayagam JB, Neubauer S, Watkins H. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: New insights from multiparametric magnetic resonance imaging. Circulation 2007; 115 (18): 2.418-2.425. DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.657023
Ismail TF, Hsu LY, Greve AM, Gonçalves C, Jabbour A, Gulati A, Hewins B, Mistry N, Wage R, Roughton M, Ferreira PF, Gatehouse P, Firmin D, O’Hanlon R, Pennell DJ, Prasad SK, Arai AE. Coronary microvascular ischemia in hypertrophic cardiomyopathy - A pixel-wise quantitative cardiovascular magnetic resonance perfusion study. J Cardiovasc Magn Reson 2014; 16: 49. DOI: https://doi.org/10.1186/s12968-014-0049-1
Sarmento BarbosaI CA, Campi de CastroI C, Rodrigues de Ávila LF, Parga FilhoI JR, Mohanad HattemII D, Arteaga Fernandez E. Realce tardío y perfusión miocárdica en cardiomiopatía hipertrófi ca (comparación entre grupos). Arq Bras Cardiol 2009; 93 (4): http://dx.doi.org/10.1590/S0066-782X2009001000017. DOI: https://doi.org/10.1590/S0066-782X2009001000017
Villa ADM, Sammut E, Zarinabad N, Carr-White G, Lee J, Bettencourt N, Razavi R, Nagel E, Chiribiri A. Microvascular ischemia in hypertrophic cardiomyopathy: New insights from high-resolution combined quantification of perfusion and late gadolinium enhancement. J Cardiovasc Magn Reson 2015; 18: 4-11.
Villa ADM, Sammut E, Zarinabad N, Carr-White G, Lee J, Bettencourt N, Razavi R, Nagel E, Chiribiri A. Microvascular ischemia in hypertrophic cardiomyopathy: New insights from high-resolution combined quantification of perfusion and late gadolinium enhancement. Journal of Cardiovascular Magnetic Resonance 2016; 18: 4-11. DOI: https://doi.org/10.1186/s12968-016-0223-8
Abdel-Aty H, Cocker M, Strohm O, Filipchuk , Friedrich MG. Abnormalities in T2-weighted cardiovascular magnetic resonance images of hypertrophic cardiomyopathy: Regional distribution and relation to late gadolinium enhancement and severity of hypertrophy. Journal of Magnetic Resonance Imaging 2008; 28: 242-245. DOI: https://doi.org/10.1002/jmri.21381
Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: Pathologic vience of myocardial ischemia. Hum Pathol 2000; 31: 988-998. DOI: https://doi.org/10.1053/hupa.2000.16659
Frustaci A, Verardo R, Caldarulo M, Acconcia MC, Russo MA, Chimenti C. Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration. Eur Heart J 2007; 28: 733-740. DOI: https://doi.org/10.1093/eurheartj/ehl525
Abdel-Aty H, Boye P, Zagrosek A. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: Comparison of diff erent approaches. J Am Coll Cardiol 2005; 45: 1.815-1.822.
Aso H, Takeda K, Ito T, Shiraishi T, Matsumura K, Nakagawa T. Assessment of myocardial fi brosis in cardiomyopathic hamsters with gadolinium- DTPA enhanced magnetic resonance imaging. Invest Radiol 1998; 33: 22-32. DOI: https://doi.org/10.1097/00004424-199801000-00004
Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989; 320: 749-755. DOI: https://doi.org/10.1056/NEJM198903233201201
Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-655. DOI: https://doi.org/10.1001/jama.281.7.650
Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: Identifi cation of high risk patients. J Am Coll Cardiol 2000; 36: 2.212-2.218. DOI: https://doi.org/10.1016/S0735-1097(00)01003-2
Maron BJ. Contemporary insights and strategies for risk stratifi cation and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 2010; 121: 445-456. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.878579
Spirito P, Autore C. Management of hypertrophic cardiomyopathy. BMJ 2006; 332: 1.251-1.255. DOI: https://doi.org/10.1136/bmj.332.7552.1251
McGill LA, Ismail TF, Nielles-Vallespin S, Ferreira P, Scott AD, Roughton M, Kilner PJ, Ho SY, McCarthy KP, Gatehouse PD, de Silva R, Speier P, Feiweier T, Mekkaoui C, Sosnovik DE, Prasad SK, Firmin DN, Pennell DJ. Reproducibility of in-vivo diff usion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2012; 24 (14): 86. DOI: https://doi.org/10.1186/1532-429X-14-86
Bogarapu S, Puchalski MD, Everitt MD, Williams RV, Weng HY, Menon SC. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT): Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy. Pediatr Cardiol 2016. Epub ahead of print. DOI: https://doi.org/10.1007/s00246-015-1329-8
Brito D, Miltenberger-Miltenyi G, Vale PS, Silva D, Diogo AN, Madeira H. Sarcomeric hypertrophic cardiomyopathy: Genetic profi le in a Portuguese population. Rev Port Cardiol 2012; 31: 577-587. DOI: https://doi.org/10.1016/j.repc.2011.12.020
Coats CJ, Elliott PM. Genetic biomarkers in hypertrophic cardiomyopathy. Biomark Med 2013; 7: 505-516. DOI: https://doi.org/10.2217/bmm.13.79
Lopes LR, Zekavati A, Syrris P, Hubank M, Giambartolomei C, Dalageorgou C, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high throughput sequencing. J Med Genet 2013; 50: 228-239. DOI: https://doi.org/10.1136/jmedgenet-2012-101270
Abdel-Razek AM, Lee LY, Tozzi R. Hypertrophic Cardiomyopathy in a Young Adult with RV Aneurysm: Report of a Rare Finding and Review of the Literature. Heart Views 2011; 12 (3): 112-117. DOI: https://doi.org/10.4103/1995-705X.95067
Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002; 105: 2.992-2.997. DOI: https://doi.org/10.1161/01.CIR.0000019070.70491.6D
Olivotto I, Maron MS, Autore C, et al. Assessment and signifi cance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 52: 559-566. DOI: https://doi.org/10.1016/j.jacc.2008.04.047
Patel P, Dhillon A, Popovic ZB, Smedira NG, Rizzo J, Thamilarasan M, Agler D, Lytle BW, Lever HM, Desai MY. Left Ventricular Outfl ow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography. Circ Cardiovasc Imaging 2015; 8: e003132. DOI: https://doi.org/10.1161/CIRCIMAGING.115.003132
Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: Clinical perspectives. J Am Coll Cardiol 2012; 60: 705-715. DOI: https://doi.org/10.1016/j.jacc.2012.02.068
Christiaans I, Lekanne dit Deprez RH, van Langen IM, Wilde AA. Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy. Heart Rhythm 2009; 6: 1.366-1.369. DOI: https://doi.org/10.1016/j.hrthm.2009.04.029
Blair E, Redwood C, Ashrafi an H, Oliveira M, Broxholme J, Kerr B, Salmon A, Ostman-Smith I, Watkins H. Mutations in the gamma(2) subunit of AMPactivated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001; 10: 1.215-1.220. DOI: https://doi.org/10.1093/hmg/10.11.1215
Weidemann F, Strotmann JM, Niemann M, et al. Heart valve involvement in Fabry cardiomyopathy. Ultrasound Med Biol 2009; 35: 730-735. DOI: https://doi.org/10.1016/j.ultrasmedbio.2008.10.010
Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I; Oudit GY. T1 Mapping With Cardiovascular MRI Is Highly Sensitive for Fabry Disease Independent of Hypertrophy and Sex. Circ Cardiovasc Imaging 2013; 6: 637-645. DOI: https://doi.org/10.1161/CIRCIMAGING.113.000482
Perugini E, Rapezzi C, Piva T, Leone O, Bacchi-Reggiani L, Riva L, et al. Noninvasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006; 92: 343-349. DOI: https://doi.org/10.1136/hrt.2005.061911
Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3: 155-164. DOI: https://doi.org/10.1016/j.jcmg.2009.09.023
Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: Noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51: 1.022-1.030. DOI: https://doi.org/10.1016/j.jacc.2007.10.049
Cobo-Marcos M, Gallego-Delgado M, Garcia-Pavia P. Aplicación práctica de la genética en el manejo de las miocardiopatías. Cardiocore 2014; 49: doi:10.1016/j.carcor.2014.02.002. DOI: https://doi.org/10.1016/j.carcor.2014.02.002
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2022 Ricardo Oscar Obregón
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
RETIC se distribuye bajo la licencia Creative Commons Reconocimiento-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0 que permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
- Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
- No comercial: no puede utilizar el material con fines comerciales.
- No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
- Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
